EVIDENCE LIBRARY
Mild Hyperekplexia Case Did Not Test Clonazepam Because It Was Not Started
A genetic case report discussed a condition often treated with clonazepam, but the child in this report was managed without it. Her outcome must not be presented as a clonazepam treatment response.
A genetic case report discussed a condition often treated with clonazepam, but the child in this report was managed without it. Her outcome must not be presented as a clonazepam treatment response.
The diagnostic change
An eighteen-month-old girl had stimulus-triggered staring and rigidity, a history of febrile seizures, and normal routine EEG and MRI findings. Genetic testing identified a de novo GLRA1 variant that the authors interpreted as confirming hyperekplexia.
The previously prescribed levetiracetam was discontinued. Because the presentation was mild, clinicians did not initiate clonazepam. At eight-month follow-up, the child had normal development and minimal non-epileptic stimulus-related symptoms.
Why the non-treatment detail matters
A medicine can appear in a paper’s discussion without having been administered. Importing expected treatment benefits from other cases would misdescribe this patient’s course.
This single report also cannot define which genetic presentations require medication or establish the long-term safety of observation. The negative nose-tap test in this child does not determine the sensitivity of that examination in all patients.
Application to evidence review
Document the actual medication administration history and the reason for the decision. The paper illustrates diagnostic refinement and a decision against clonazepam in one mild presentation. It supplies no measured clonazepam efficacy, adverse-event rate, or dose–response evidence.
Source paper
Original analysis of the supplied journal article, identified as PMC12851740.